Transcriptomic profiling of melanomas treated with BRAF inhibitor

Since tumor early response is a timing sensitive progress, accurate time points for biopsy collection will provide a fundament for the investigation of the correlation between angiogenesis and BRAFi resistance. To this end, we recapitulated the clinical therapeutic process with a mouse model. SMM102, a BRAFi sensitive mouse cell line, was subcutaneously inoculated on both flanks of C57BL/6 mice. Mice were treated with BRAFi and sacrificed at different time point. Overall design: C57BL/6J mice (female, 6-8 weeks old) were subcutaneously injected with 1x105 SMM102 cells, two injections per mouse. Once tumors volumes reached 150-300 mm3, mice were treated with vehicle or PLX4032 (50 mg/kg, 5 days per week) by intraperitoneal injection (IP). Mice were sacrificed at day 3 and 6 for vehicle group. And for PLX4032 group, mice were sacrificed at day 3, 6, 18 and 27.